Sensei Biotherapeutics Q1 2025 Earnings Report

Sensei Biotherapeutics EPS Results

• Actual EPS: -$5.40
• Consensus EPS: -$4.20
• Beat/Miss: Missed by -$1.20
• One Year Ago EPS: N/A

Sensei Biotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sensei Biotherapeutics Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 6, 2025
• Conference Call Time: 7:00AM ET

Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical‐stage biotechnology company dedicated to advancing novel immuno‐oncology therapies by targeting innate immune checkpoints. The company leverages a proprietary discovery and engineering platform to identify and develop monoclonal antibodies that modulate macrophage and myeloid cell activity within the tumor microenvironment. Sensei’s lead candidates are designed to enhance anti‐tumor immune responses by disrupting inhibitory signals that often allow cancer cells to evade the immune system.

Sensei’s pipeline includes multiple therapeutic programs, with lead assets focused on solid tumors and hematologic malignancies. These include monoclonal antibodies directed against key immune-regulatory proteins such as signal regulatory protein alpha (SIRPα) and other novel targets identified through the company’s platform. Preclinical studies have demonstrated the potential for these agents to synergize with existing immunotherapies, such as checkpoint inhibitors, and chemotherapy, supporting ongoing clinical trials across diverse cancer types.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Sensei Biotherapeutics operates research facilities in the United States and maintains collaborative partnerships with leading academic institutions in Europe. The company has grown rapidly, fueled by strategic licensing agreements and research collaborations that provide access to cutting‐edge genomic and proteomic technologies. Sensei’s global focus aims to accelerate development timelines and expand patient access to innovative cancer treatments.

Under the leadership of Chief Executive Officer Carsten Schroeder, Sensei’s management team brings extensive experience in antibody discovery, clinical development, and commercial strategy. The board of directors comprises industry veterans with deep expertise in immuno‐oncology, regulatory affairs, and global market access. Together, Sensei Biotherapeutics is committed to translating its scientific insights into transformative therapies for patients facing cancer.